Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1584706 | 0.98 | CA1 (0.48) | CA1CA2CA9ALDH1A1MAPK1 | |
| SCHEMBL8030121 | 0.82 | MAPT (0.50) | CA1CA2CA9ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL3324974 | 0.80 | MAPT (0.48) | CA1CA2CA9ALDH1A1MAPK1 | |
| SCHEMBL2137896 | 0.77 | CA1 (0.50) | CA1CA2CA9ALDH1A1HTT | |
| SCHEMBL12883444 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPK1HTTKMT2ALMNA | |
| SCHEMBL177020 | 0.76 | CA1 (0.53) | CA1CA2CA9ALDH1A1MAPK1 | |
| SCHEMBL1999703 | 0.76 | ALOX15 (0.42) | CA1CA2CA9ALDH1A1MAPK1 | |
| SCHEMBL29573961 | 0.76 | CA1 (0.53) | CA1CA2CA9ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL855505 | 0.76 | CA1 (0.48) | CA1CA2CA9ALDH1A1HTT | |
| SCHEMBL11087624 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MAPK1HTTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| CN-113454070-A | Cinnoline compounds and their use for the treatment of HPK 1-dependent disorders such as cancer | 豪夫迈·罗氏有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3856724-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| CN-1980664-B | CRTH2 receptor ligands for therapeutic use | 7TM PHARMA AS | 2011-02-23 | — | — | CN | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| CN-1980664-A | CRTH2 receptor ligands for therapeutic use | 7TM PHARMA AS (DK) | 2007-06-13 | — | — | CN | disclosed |
| EP-1758579-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115382-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
| US-6174912-B1 | FOR TREATING PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING MAJOR DEPRESSION, ANXIETY-RELATED DISORDERS, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY AND FEEDING DISORDERS AS WELL AS TREATMENT OF IMMUNOLOGICAL DISEASES | DUPONT PHARMACEUTICALS COMPANY | 2001-01-16 | — | — | US | disclosed |
| EP-0937081-A1 | NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999010350-A1 | NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | CA1 3402/4885CA2 3148/4885CA9 3101/4885 |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | HRH1, HRH2, HRH3 | CA1 2838/4885CA2 1503/4885CA9 2144/4885 |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | CA1 3402/4885CA2 3148/4885CA9 3101/4885 |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CA1 1757/4885CA2 909/4885CA9 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.